• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Change Healthcare Launches COVID-19 Research Database Using De-Identified Data to Track Disease Progression

by Fred Pennic 05/13/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
AMA to Fast Track New CPT Code for Novel Coronavirus Test Coronavirus (COVID-19) Outbreak Monitoring Platform

What You Should Know:

– Change Healthcare announced a new online COVID-19 research database to track disease progression, treatment efficacy, for qualified public and private healthcare organizations using de-identified data to understand disease progression and improve intervention.

– Actionable insight “beyond the diagnosis” enables health researchers to better understand COVID-19 progression, intervention effectiveness, and impacts on the healthcare system.


Today Change Healthcare launched Market Insights: COVID-19 Analytic Data Sets, an online COVID-19 research environment providing consolidated, de-identified, and timely analytic data relevant to the COVID-19 pandemic for qualified public and private healthcare organizations. The online research environment combines leverages de-identified claims data, enabling researchers to move beyond test and diagnosis counts into real understanding of disease progression, intervention effectiveness, and impacts upon the healthcare system.

Use De-Identified Data to Understand Disease Progression and Improve Intervention

The remediation of COVID-19 has been hampered by limited data. Researchers need more than daily counts of diagnoses and tests to truly understand the disease. Given the complexity of COVID-19, analyses require comprehensive, timely, and statistically meaningful data.

Most COVID-19 data are limited to static reports on the number of new cases, overall cases, deaths, and geographical impact. While useful in preparing for resource allocation, it provides no insight into the disease progression and the efficacy of interventions––the type of data the medical community needs to take action.

Change Healthcare processes billions of U.S. medical and pharmacy claims every year, now including those related to COVID-19. Claims provide a more comprehensive view beyond the test or diagnosis, including other diagnoses, past care, and social determinants of health. Additionally, claims are coded by medical professionals without relying on self-reported patient data.

Enable Longitudinal Analysis

Market Insights: COVID-19 Analytic Data Sets isolates claims into three unique data sets, all of which are de-identified and contractually permission:

1. Claims with explicit COVID-19 test and diagnosis codes

The first analytic data set includes claims with an explicit SARS-CoV-2/COVID-19 test or diagnosis code.

2. Claims with codes identified in the February CDC interim billing guidelines

The second analytic data set includes claims that contain billing codes specified in the interim billing guidelines issued by CDC in February 20202, indicating SARS-CoV-2/COVID-19 activity.

3. Claims with respiratory management diagnosis codes

The third analytic data set includes HCPCS claims related to respiratory management which were used to code early cases of the virus.

These datasets are comprehensive, timely, and statistically meaningful for a variety of research initiatives. Each dataset includes de-identified claims containing selected tests, diagnoses, or procedures of up to four years’ history. The datasets are updated daily as new information is processed.

“COVID researchers need more comprehensive and timely data in an environment where advanced data science can be responsibly performed,” said Tim Suther, senior vice president of Data Solutions at Change Healthcare. “These data sets enable robust analysis by the country’s leading medical data scientists to understand actual disease progression, the effectiveness of various interventions, and impacts to the healthcare system overall.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Change Healthcare, Coronavirus (COVID-19), dataset, Pharmacy, Social Determinants of Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |